GSK's David Leather On Transitioning from GP And Radio Doctor To Real World-Evidence Czar
Executive Summary
Leather – the man behind GlaxoSmithKline's ground-breaking real-world evidence initiative, the Salford Lung Study – is GSK’s in-house RWE expert. He spoke with the Pink Sheet about a range of topics, including how Salford might influence the development of RWE.
You may also be interested in...
Real-World Evidence: Lessons From GSK's Salford Lung Study
The Salford Lung Study is pioneering in the emerging field of gathering real-world evidence. David Leather, Global Medical Affairs Leader in the Respiratory Franchise at GSK, led the UK-based study and talked to the Pink Sheet about why it was important for GSK and what may come next.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.